By Deena Beasley Oct 7 (Reuters) – Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Jan Wolfe WASHINGTON, Oct 7 (Reuters) - Democratic Party officials sued US President Donald…
By Stephen Nellis SAN FRANCISCO, Oct 7 (Reuters) - Microsoft unveiled on Wednesday an AI…
RPT- ORACLE, BROADCOM AND SPACEX SEEK DEBT DEALS TO PAY FOR AI CHIPS - WSJ…
By Howard Schneider WASHINGTON, Oct 7 (Reuters) - Federal Reserve policymakers were divided last month…
* Plaintiffs seek injunction requiring Missouri to fully match Lincoln's federal land-grant funding in future…
By Elizabeth Howcroft PARIS, Oct 7 (Reuters) - Revolut will cover the cost of customers…